“Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT”, J of Skin, vol. 8, no. 6, p. s433, Nov. 2024, doi: 10.25251/skin.8.supp.433.